Vital Pharma Research

1. Teva Pharmaceuticals USA, Inc. $195,425 5 payments
2. Sumitomo Pharma America, Inc. $96,090 45 payments
3. Pfizer Inc. $19,658 3 payments
4. Taro Pharmaceuticals USA, Inc. $6,845 1 payment
5. Abbott Laboratories $3,800 2 payments
6. Novartis Pharmaceuticals Corporation $2,468 2 payments

1. A Randomized, Double Blind, Parallel Group, Three Arm, Placebo Controlled, Multi-Site Therapeutic Equivalence Study With Clinical End-points Comparing Test Product "Oxymetazoline Hydrochloride Cream, 1%" to Reference Product "RHOFADETM Cream, 1%" in the Treatment of Moderate to Severe Persistent Facial Erythema of Rosacea $195,425 5 payments
2. A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids Or Endometriosis $90,398 42 payments
3. A Phase 1 Openlabel Study to Evaluate the Pharmacokinetics Safety and Tolerability of Orally Administered Nirmatrelvirritonavir in Pregnant Women With Mildtomoderate Covid19 $19,658 3 payments
4. Adrenal Suppression and Pharmacokinetics of Topicort Spray, 0.25 in Pediatric Patients With Plaque Psoriasis $6,845 1 payment
5. A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy $5,692 3 payments
6. Prospective Specimen Collection from Self-reported Drug Users for the Design & Development of ARDx Drugs of Abuse Assays $3,800 2 payments
7. A 52 Week Multicenter Randomized Double Blind Placebocontrolled Study to Assess the Efficacy and Safety of Qaw039 When Added to Existing Asthma Therapy in Patients With Uncontrolled Severe Asthma $2,468 2 payments

1. Other $6,845 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.